Cost-Effectiveness Model of Cytomegalovirus Management Strategies in Renal Transplantation
- 1 September 2000
- journal article
- research article
- Published by Springer Science and Business Media LLC in PharmacoEconomics
- Vol. 18 (3), 239-251
- https://doi.org/10.2165/00019053-200018030-00004
Abstract
No abstract availableKeywords
This publication has 39 references indexed in Scilit:
- Valacyclovir for the Prevention of Cytomegalovirus Disease after Renal TransplantationNew England Journal of Medicine, 1999
- LONG-TERM GRAFT OUTCOME IS NOT NECESSARILY AFFECTED BY DELAYED ONSET OF GRAFT FUNCTION AND EARLY ACUTE REJECTION1Transplantation, 1997
- A Utility Assessment of Oral and Intravenous Ganciclovir for the Maintenance Treatment of AIDS-Related Cytomegalovirus RetinitisPharmacoEconomics, 1996
- A PROSPECTIVE RANDOMIZED STUDY OF ACYCLOVIR VERSUS GANCICLOVIR PLUS HUMAN IMMUNE GLOBULIN PROPHYLAXIS OF CYTOMEGALOVIRUS INFECTION AFTER SOLID ORGAN TRANSPLANTATION1,2Transplantation, 1994
- CYTOMEGALOVIRUS INFECTION—AN ETIOLOGICAL FACTOR FOR REJECTION? A PROSPECTIVE STUDY IN 242 RENAL TRANSPLANT PATIENTSTransplantation, 1993
- Current management of cytomegalovirus diseaseJournal of Medical Virology, 1993
- THE INCIDENCE AND IMPACT OF EARLY REJECTION EPISODES ON GRAFT OUTCOME IN RECIPIENTS OF FIRST CADAVER KIDNEY TRANSPLANTSTransplantation, 1992
- A Randomized, Placebo-Controlled Trial of Oral Acyclovir for the Prevention of Cytomegalovirus Disease in Recipients of Renal AllograftsNew England Journal of Medicine, 1989
- Use of Cytomegalovirus Immune Globulin to Prevent Cytomegalovirus Disease in Renal-Transplant RecipientsNew England Journal of Medicine, 1987
- Virus infections after transplantation in manArchiv für die gesamte Virusforschung, 1977